The FDA has approved Xeris Biopharma’s Recorlev (levoketoconazole) for treating hypercortisolemia in adults with Cushing’s syndrome who are unable to undergo surgery.
Source: Drug Industry Daily
The FDA has approved Xeris Biopharma’s Recorlev (levoketoconazole) for treating hypercortisolemia in adults with Cushing’s syndrome who are unable to undergo surgery.
Source: Drug Industry Daily